CompanyGraph
Beam Therapeutics designs gene-editing therapies for serious diseases, earning through collaboration and licensing agreements with larger drug makers while its own candidates remain in development rather than on the market.
- Valued far above the size of its business
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$241.84M, lower than 95% of all stocks globally
- PositionOperating margin is -25827.1%, lower than 95% of its Biotechnology peers (median -24.1%)
- Interpretations2 currently firing — 2
What this company is and how it runs — written from structure, not news.
The system coordinates scientific work on a gene-editing platform with a staged pipeline of drug candidates, each of which must clear a long approval process before it can earn anything, and it routes some of those candidates to larger partners through co-development or licensing instead of carrying every one to market alone. It sits upstream of its industry, feeding more industries downstream than the number it draws on upstream.
What revenue this business earns looks tied to collaboration and licensing arrangements rather than to sales of an approved product, and that revenue is small next to what it spends on research, since research costs and stock-based pay both take up a large share of it. It has recorded net losses in multiple recent years, and it has covered that shortfall mainly by drawing on equity and cash rather than by taking on debt, which has instead been shrinking.
This company is valued well above what its current business generates, which fits a system whose worth rests on the future potential of candidates still working through a long approval process rather than on present output. It has grown partly by issuing more shares over time, so its scale so far reflects raised capital more than revenue growth or reinvested earnings, a pattern CompanyGraph reads as common across the large group of companies running this same kind of system rather than distinct to this one.
CompanyGraph's mapping of related industries shows this company drawing on a small number of other industries for what it needs to operate. Beyond that broad industry-level position, CompanyGraph does not have this company's own disclosures about specific suppliers, single-source inputs, or named dependencies, so nothing more specific can be said here.
CompanyGraph's mapping shows this company feeding a larger number of other industries than the number it depends on, consistent with sitting upstream among the industries it operates alongside. CompanyGraph does not have this company's own disclosures about which customers or partners make up that dependence, or how concentrated it is, so that detail is not visible here.
CompanyGraph places this company within a sizeable group of other companies that run the same kind of system, developing candidates that must each clear a long approval process before earning anything. That count describes how common this operating shape is, not how hard any single company's version of it would be for a rival to copy, and CompanyGraph does not have evidence about competitors' own capabilities to support a claim of that kind here.
CompanyGraph's general model for this class of company treats the regulatory approval gate, the point at which a candidate is allowed to earn anything at all, as the limit most likely to shape its scale. This is a general starting assumption for the kind of system this company runs, not a measurement CompanyGraph has confirmed against this business's own stated capacity or timeline, which is not visible here.
CompanyGraph's general framework for this kind of company identifies the long, binary process of regulatory approval as the main outside force acting on it, since a candidate earns nothing until it clears that process. This is a model for this whole class of company rather than something confirmed from this business's own disclosures about its regulators, legal proceedings, or trade exposure, none of which is visible here.
Read from figures CompanyGraph recomputed from this company's statements and from its structural position. Written September 2026. A question with no evidence behind it is left out rather than answered.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
- Valued far above the size of its business
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Is this company growing?
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Structural Tensions
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.